Combination
AssigneeNovartis AG
InventorsMark J. Cornfeld, Rakesh Kumar, Shannon Renae Morris
Life of this patent
Estimating the term…
Abstract
A novel combination comprising a 17 α-hydroxylase/C17,20 lyase inhibitor, for example: (3β)-17-(pyridin-3-yl)androsta-5,18-dien-3-ol or a pharmaceutically acceptable salt or ester thereof, and an AKT inhibitor, for example: N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, and optional additional antineoplastic agents; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of 17 α-hydroxylase/C17,20 lyase and/or AKT inhibition is beneficial, e.g., cancer.
Claims13
A combination comprising:
- (i) CFG920,
- or a pharmaceutically acceptable salt or ester thereof;
- and
- (ii) a compound of Structure (II)
- or a pharmaceutically acceptable salt thereof.
-3. (canceled)
-8. (canceled)
A method of treating prostate cancer in a human in need thereof which comprises the administration of a therapeutically effective amount of
- (i) CFG920,
- or a pharmaceutically acceptable salt or ester thereof;
- and
- (ii) a compound of Structure (II)
- or a pharmaceutically acceptable salt thereof for use in therapy.
(canceled)
(canceled)
-53. (canceled)
Dependencies are inferred from the claim text.